

**OMEPRAZOLE - omeprazole capsule, delayed release**  
**Altura Pharmaceuticals, Inc.**

-----  
**HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use Omeprazole Delayed-Release Capsules safely and effectively. See full prescribing information for Omeprazole Delayed-Release Capsules.**

**Initial U.S. Approval: 2002**

----- **RECENT MAJOR CHANGES** -----

Indications and Usage, Treatment of Gastroesophageal Reflux Disease (1.3) 03/2008

Dosage and Administration, Pediatric Patients (2.7) 03/2008

----- **DOSAGE AND ADMINISTRATION** -----

<b>Indication</b>	<b>Omeprazole Dose</b>	<b>Frequency</b>
<b>Short-Term Treatment of Active Duodenal Ulcer (2.1)</b>	20 mg	Once daily for 4 weeks. Some patients may require an additional 4 weeks
<b>H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (2.2)</b>		
<i>Triple Therapy:</i>		
Omeprazole Delayed-Release Capsules	20 mg	Each drug twice daily for 10 days
Amoxicillin	1000 mg	
Clarithromycin	500 mg	
<i>Dual Therapy:</i>		
Omeprazole Delayed-Release Capsules	40 mg	Once daily for 14 days
Clarithromycin	500 mg	Three times daily for 14 days
<b>Gastric Ulcer (2.3)</b>	40 mg	Once daily for 4 to 8 weeks
<b>GERD (2.4)</b>	20 mg	Once daily for 4 to 8 weeks
<b>Maintenance of Healing of Erosive Esophagitis (2.5)</b>	20 mg	Once daily
<b>Pathological Hypersecretory Conditions (2.6)</b>	60 mg (varies with individual patient)	Once daily
<b>Pediatric Patients (2 to 16 years of age) (2.7)</b>		
<b>GERD</b>	Weight            Dose	Once daily
<b>And Maintenance of Healing of Erosive Esophagitis</b>	10 < 20 kg      10 mg	
	> 20 kg          20 mg	

----- **DOSAGE FORMS AND STRENGTHS** -----

Omeprazole Delayed-Release Capsules, 10 mg, 20 mg and 40 mg (3)

----- **CONTRAINDICATIONS** -----

Known hypersensitivity to any component of the formulation (4)

----- **WARNINGS AND PRECAUTIONS** -----

Concomitant Gastric Malignancy: Symptomatic response to therapy with Omeprazole Delayed-Release Capsules does not preclude the presence of gastric malignancy (5.1)

Atrophic Gastritis: Has been observed in gastric corpus biopsies from patients treated long-term with Omeprazole Delayed-Release Capsules (5.2)

Combination Use with Clarithromycin and/or Amoxicillin: Refer to full prescribing information for individual drugs when used in combination (5.3, 5.4)

----- **ADVERSE REACTIONS** -----

Adults: Most common adverse reactions (incidence  $\geq 2\%$ ) are:

headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence. (6)

Pediatric patients (2 - 16 years of age):

Safety profile similar to that in adults, except that respiratory system events and fever were the most frequently reported reactions in pediatric studies. (8.4)

**To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. 1-800-477-7877 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)**

----- **DRUG INTERACTIONS** -----

Drugs for which gastric pH can affect bioavailability (e.g., ketoconazole, ampicillin esters, iron salts): Omeprazole Delayed-Release Capsules may interfere with absorption due to inhibition of gastric acid secretion (Z)

Drugs metabolized by cytochrome P450 (e.g., diazepam, warfarin, phenytoin, cyclosporine, disulfiram, benzodiazepines): Omeprazole Delayed-Release Capsules can prolong their elimination. Monitor to determine need for possible dose adjustments when taken with Omeprazole Delayed-Release Capsules (Z)

Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time (Z)

Voriconazole: May increase plasma levels of omeprazole (Z)

Atazanavir: Omeprazole Delayed-Release Capsules may reduce plasma levels of atazanavir (Z)

Tacrolimus: Omeprazole Delayed-Release Capsules may increase serum levels of tacrolimus (Z)

----- **USE IN SPECIFIC POPULATIONS** -----

Hepatic Impairment:

Consider dose reduction, particularly for maintenance of healing of erosive esophagitis (12.3)

Asian Patients:

Consider dose reduction, particularly for maintenance of healing of erosive esophagitis (12.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 4/2010

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

- 1.1 Duodenal Ulcer (adults)
- 1.2 Gastric Ulcer (adults)
- 1.3 Treatment of Gastroesophageal Reflux Disease (GERD) (adults and pediatric patients)
- 1.4 Maintenance of Healing of Erosive Esophagitis (adults and pediatric patients)
- 1.5 Pathological Hypersecretory Conditions (adults)

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Short-Term Treatment of Active Duodenal Ulcer
- 2.2 *H. pylori* Eradication for the Reduction of the Risk of Duodenal Ulcer Recurrence
- 2.3 Gastric Ulcer
- 2.4 Gastroesophageal Reflux Disease (GERD)
- 2.5 Maintenance of Healing of Erosive Esophagitis
- 2.6 Pathological Hypersecretory Conditions
- 2.7 Pediatric Patients
- 2.8 Alternative Administration Options

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Concomitant Gastric Malignancy
- 5.2 Atrophic Gastritis
- 5.3 Combination Use of Omeprazole Delayed-Release Capsules with Amoxicillin
- 5.4 Combination Use of Omeprazole Delayed-Release Capsules with Clarithromycin

**6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience with Omeprazole Delayed-Release Capsules Monotherapy
- 6.2 Clinical Trials Experience with Omeprazole Delayed-Release Capsules in Combination Therapy for *H. pylori* Eradication
- 6.3 Post-marketing Experience

**7 DRUG INTERACTIONS**

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment
- 8.8 Asian Population

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

Geriatric Population

Pediatric Use

*Hepatic Impairment*

*Renal Impairment*

*Asian Population*

12.4 Microbiology Information in *H. pylori*

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

**14 CLINICAL STUDIES**

- 14.1 Duodenal Ulcer Disease
- 14.2 Gastric Ulcer
- 14.3 Gastroesophageal Reflux Disease (GERD)
- 14.4 Erosive Esophagitis
- 14.5 Pathological Hypersecretory Conditions
- 14.6 Pediatric GERD

**15 REFERENCES**

**16 HOW SUPPLIED/STORAGE AND HANDLING**

Storage

**17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

**FULL PRESCRIBING INFORMATION**



**1 INDICATIONS AND USAGE**

Omeprazole Delayed-Release Capsules are a proton pump inhibitor indicated for:

- Treatment of duodenal ulcer in adults (1.1)
- Treatment of gastric ulcer in adults (1.2)
- Treatment of gastroesophageal reflux disease (GERD) in pediatric patients and adults (1.3)
- Maintenance of healing of erosive esophagitis in pediatric patients and adults (1.4)
- Treatment of pathological hypersecretory conditions in adults (1.5)

The safety and effectiveness of Omeprazole Delayed-Release Capsules in pediatric patients < 1 year of age have not been established. (8.4)

### **1.1 Duodenal Ulcer (adults)**

Omeprazole Delayed-Release Capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

Omeprazole Delayed-Release Capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with *H. pylori* infection and duodenal ulcer disease (active or up to 1-year history) to eradicate *H. pylori* in adults.

Omeprazole Delayed-Release Capsules, in combination with clarithromycin are indicated for treatment of patients with *H. pylori* infection and duodenal ulcer disease to eradicate *H. pylori* in adults.

Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence [see *Clinical Studies* (14.1) and *Dosage and Administration* (2)].

Among patients who fail therapy, omeprazole with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted. [See *Microbiology* (12.4)], and the clarithromycin package insert, Microbiology section.)

### **1.2 Gastric Ulcer (adults)**

Omeprazole Delayed-Release Capsules are indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer in adults. [See *Clinical Studies* (14.2)]

### **1.3 Treatment of Gastroesophageal Reflux Disease (GERD) (adults and pediatric patients)**

#### *Symptomatic GERD*

Omeprazole Delayed-Release Capsules are indicated for the treatment of heartburn and other symptoms associated with GERD in pediatric patients and adults.

#### *Erosive Esophagitis*

Omeprazole Delayed-Release Capsules are indicated for the short-term treatment (4-8 weeks) of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults. [See *Clinical Studies* (14.4)]

The efficacy of omeprazole used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of erosive esophagitis or GERD symptoms (e.g., heartburn), additional 4-8 week courses of omeprazole may be considered.

### **1.4 Maintenance of Healing of Erosive Esophagitis (adults and pediatric patients)**

Omeprazole Delayed-Release Capsules are indicated to maintain healing of erosive esophagitis in pediatric patients and adults.

Controlled studies do not extend beyond 12 months. [See *Clinical Studies* (14.4)]

### **1.5 Pathological Hypersecretory Conditions (adults)**

Omeprazole Delayed-Release Capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

## 2 DOSAGE AND ADMINISTRATION

Omeprazole Delayed-Release Capsule should be taken before eating. In the clinical trials, antacids were used concomitantly with omeprazole.

Patients should be informed that the Omeprazole Delayed-Release Capsules should be swallowed whole.

For patients unable to swallow an intact capsule, alternative administration options are available. [See *Dosage and Administration* (2.8)]

### 2.1 Short-Term Treatment of Active Duodenal Ulcer

The recommended adult oral dose of Omeprazole Delayed-Release Capsules is 20 mg once daily. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

### 2.2 *H. pylori* Eradication for the Reduction of the Risk of Duodenal Ulcer Recurrence

*Triple Therapy (omeprazole/clarithromycin/amoxicillin)*— The recommended adult oral regimen is omeprazole 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg each given twice daily for 10 days. In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

*Dual Therapy (omeprazole/clarithromycin)*— The recommended adult oral regimen is omeprazole 40 mg once daily plus clarithromycin 500 mg three times daily for 14 days. In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of omeprazole 20 mg once daily is recommended for ulcer healing and symptom relief.

### 2.3 Gastric Ulcer

The recommended adult oral dose is 40 mg once daily for 4-8 weeks.

### 2.4 Gastroesophageal Reflux Disease (GERD)

The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.

### 2.5 Maintenance of Healing of Erosive Esophagitis

The recommended adult oral dose is 20 mg daily. [See *Clinical Studies* (14.4) ]

### 2.6 Pathological Hypersecretory Conditions

The dosage of omeprazole in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 120 mg three times daily have been administered. Daily dosages of greater than 80 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with omeprazole for more than 5 years.

### 2.7 Pediatric Patients

For the treatment of GERD and maintenance of healing of erosive esophagitis, the recommended daily dose for pediatric patients 2 to 16 years of age is as follows:

---

Patient	Omeprazole
---------	------------

Weight	Daily Dose
10 < 20 kg	10 mg
≥ 20 kg	20 mg

On a per kg basis, the doses of omeprazole required to heal erosive esophagitis in pediatric patients are greater than those for adults.

Alternative administrative options can be used for pediatric patients unable to swallow an intact capsule [See *Dosage and Administration* (2.8)].

## 2.8 Alternative Administration Options

Omeprazole is available as a delayed-release capsule.

For patients who have difficulty swallowing capsules, the contents of a Omeprazole Delayed-Release Capsules can be added to applesauce. One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the microtablets inside the capsule should be carefully emptied on the applesauce. The microtablets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the microtablets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The microtablets should not be chewed or crushed. The microtablets/applesauce mixture should not be stored for future use.

## 3 DOSAGE FORMS AND STRENGTHS

Omeprazole Delayed-Release Capsules, 10 mg, are opaque white cap and opaque white body capsules imprinted with “KU” and “114” in black ink.

Omeprazole Delayed-Release Capsules, 20 mg, are opaque white cap and opaque gold body capsules imprinted with “KU” and “118” in black ink.

Omeprazole Delayed-Release Capsules, 40 mg, are opaque gold cap and opaque gold body capsules imprinted with “KU” and “136” in black ink.

## 4 CONTRAINDICATIONS

Omeprazole Delayed-Release Capsules are contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, and urticaria [see *Adverse Reactions* (6)].

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Concomitant Gastric Malignancy

Symptomatic response to therapy with omeprazole does not preclude the presence of gastric malignancy.

### 5.2 Atrophic Gastritis

Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long-term with omeprazole.

### 5.3 Combination Use of Omeprazole Delayed-Release Capsules with Amoxicillin

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Before initiating therapy with

amoxicillin, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens. If an allergic reaction occurs, amoxicillin should be discontinued and appropriate therapy instituted. Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids and airway management, including intubation, should also be administered as indicated.

Pseudomembranous colitis has been reported with nearly all antibacterial agents and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of “antibiotic-associated colitis.”

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.

#### **5.4 Combination Use of Omeprazole Delayed-Release Capsules with Clarithromycin**

Clarithromycin should not be used in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking clarithromycin, the patient should be apprised of the potential hazard to the fetus. (See Warnings in prescribing information for clarithromycin.)

Co-administration of omeprazole and clarithromycin has resulted in increases in plasma levels of omeprazole, clarithromycin, and 14-hydroxy-clarithromycin. [See *Clinical Pharmacology* (12) ]

Concomitant administration of clarithromycin with cisapride or pimozone, is contraindicated.

## **6 ADVERSE REACTIONS**

### **6.1 Clinical Trials Experience with Omeprazole Delayed-Release Capsules Monotherapy**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflects exposure to omeprazole in 3096 patients from worldwide clinical trials (465 patients from US studies and 2,631 patients from international studies). Indications clinically studied in US trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate  $\geq 2\%$ ) from omeprazole-treated patients enrolled in these studies included headache (6.9%), abdominal pain (5.2%), nausea (4.0%), diarrhea (3.7%), vomiting (3.2%), and flatulence (2.7%).

Additional adverse reactions that were reported with an incidence  $\geq 1\%$  included acid regurgitation (1.9%), upper respiratory infection (1.9%), constipation (1.5%), dizziness (1.5%), rash (1.5%), asthenia (1.3%), back pain (1.1%), and cough (1.1%).

The clinical trial safety profile in patients greater than 65 years of age was similar to that in patients 65 years of age or less.

The clinical trial safety profile in pediatric patients who received omeprazole was similar to that in adult patients. Unique to the pediatric population, however, adverse reactions of the respiratory system were most frequently reported in the 2 to 16 year age groups (18.5%). Similarly, accidental injuries were reported frequently in the 2 to 16 year age group (3.8%). [See *Use in Specific Populations* (8.4) ]

## 6.2 Clinical Trials Experience with Omeprazole Delayed-Release Capsules in Combination Therapy for *H. pylori* Eradication

In clinical trials using either dual therapy with omeprazole and clarithromycin, or triple therapy with omeprazole, clarithromycin, and amoxicillin, no adverse reactions unique to these drug combinations were observed. Adverse reactions observed were limited to those previously reported with omeprazole, clarithromycin, or amoxicillin alone.

### *Dual Therapy (omeprazole/clarithromycin)*

Adverse reactions observed in controlled clinical trials using combination therapy with omeprazole and clarithromycin (n = 346) that differed from those previously described for omeprazole alone were taste perversion (15%), tongue discoloration (2%), rhinitis (2%), pharyngitis (1%) and flu-syndrome (1%). (For more information on clarithromycin, refer to the clarithromycin prescribing information, Adverse Reactions section).

### *Triple Therapy (omeprazole/clarithromycin/amoxicillin)*

The most frequent adverse reactions observed in clinical trials using combination therapy with omeprazole, clarithromycin, and amoxicillin (n = 274) were diarrhea (14%), taste perversion (10%), and headache (7%). None of these occurred at a higher frequency than that reported by patients taking antimicrobial agents alone. (For more information on clarithromycin or amoxicillin, refer to the respective prescribing information, Adverse Reactions sections).

## 6.3 Post-marketing Experience

The following adverse reactions have been identified during post-approval use of Omeprazole Delayed-Release Capsules. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their actual frequency or establish a causal relationship to drug exposure.

*Body As a Whole:* Hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria, (see also *Skin* below); fever; pain; fatigue; malaise;

*Cardiovascular:* Chest pain or angina, tachycardia, bradycardia, palpitations, elevated blood pressure, peripheral edema

*Endocrine:* Gynecomastia

*Gastrointestinal:* Pancreatitis (some fatal), anorexia, irritable colon, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, stomatitis, abdominal swelling, dry mouth. During treatment with omeprazole, gastric fundic gland polyps have been noted rarely. These polyps are benign and appear to be reversible when treatment is discontinued. Gastroduodenal carcinoids have been reported in patients with ZE syndrome on long-term treatment with omeprazole. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.

*Hepatic:* Liver disease including hepatic failure (some fatal), liver necrosis (some fatal), hepatic encephalopathy hepatocellular disease, cholestatic disease, mixed hepatitis, jaundice, and elevations of liver function tests [ALT, AST, GGT, alkaline phosphatase, and bilirubin]

*Metabolic/Nutritional:* Hypoglycemia, hyponatremia, weight gain

*Musculoskeletal:* Muscle weakness, myalgia, muscle cramps, joint pain, leg pain

*Nervous System/Psychiatric:* Psychiatric and sleep disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, apathy, somnolence, anxiety, and dream abnormalities; tremors, paresthesia; vertigo

*Respiratory:* Epistaxis, pharyngeal pain

*Skin:* Severe generalized skin reactions including toxic epidermal necrolysis (some fatal), Stevens-



Johnson syndrome, and erythema multiforme; photosensitivity; urticaria; rash; skin inflammation; pruritus; petechiae; purpura; alopecia; dry skin; hyperhidrosis

*Special Senses:* Tinnitus, taste perversion

*Ocular:* Optic atrophy, anterior ischemic optic neuropathy, optic neuritis, dry eye syndrome, ocular irritation, blurred vision, double vision

*Urogenital:* Interstitial nephritis, hematuria, proteinuria, elevated serum creatinine, microscopic pyuria, urinary tract infection, glycosuria, urinary frequency, testicular pain

*Hematologic:* Agranulocytosis (some fatal), hemolytic anemia, pancytopenia, neutropenia, anemia, thrombocytopenia, leukopenia, leucocytosis

## 7 DRUG INTERACTIONS

*Drugs for which gastric pH can affect bioavailability*

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole.

*Drugs metabolized by cytochrome P450 (CYP)*

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time.

Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole.

Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered. When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state  $C_{max}$  and  $AUC_{0-24}$  of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given without voriconazole.

*Atazanavir*

Concomitant use of atazanavir and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.

*Tacrolimus* Concomitant administration of omeprazole and tacrolimus may increase the serum levels of tacrolimus.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

Reproductive studies in rats and rabbits with omeprazole and multiple cohort studies in pregnant women with omeprazole use during the first trimester do not show an increased risk of congenital anomalies or

adverse pregnancy outcomes. There are no adequate and well controlled studies on the use of omeprazole in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. The vast majority of reported experience with omeprazole during human pregnancy is first trimester exposure and the duration of use is rarely specified, e.g., intermittent vs. chronic. An expert review of published data on experiences with omeprazole use during pregnancy by TERIS – the Teratogen Information System – concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as fair). Three epidemiological studies compared the frequency of congenital abnormalities among infants born to women who used omeprazole during pregnancy with the frequency of abnormalities among infants of women exposed to H<sub>2</sub>-receptor antagonists or other controls. A population-based prospective cohort epidemiological study from the Swedish Medical Birth Registry, covering approximately 99% of pregnancies, reported on 955 infants (824 exposed during the first trimester with 39 of these exposed beyond first trimester, and 131 exposed after the first trimester) whose mothers used omeprazole during pregnancy. *In utero* exposure to omeprazole was not associated with increased risk of any malformation (odds ratio 0.82, 95% CI 0.50–1.34), low birth weight or low Apgar score. The number of infants born with ventricular septal defects and the number of stillborn infants was slightly higher in the omeprazole-exposed infants than the expected number in the normal population. The author concluded that both effects may be random.

A retrospective cohort study reported on 689 pregnant women exposed to either H<sub>2</sub>-blockers or omeprazole in the first trimester (134 exposed to omeprazole). The overall malformation rate was 4.4% (95% CI 3.6–5.3) and the malformation rate for first trimester exposure to omeprazole was 3.6% (95% CI 1.5–8.1). The relative risk of malformations associated with first trimester exposure to omeprazole compared with non-exposed women was 0.9 (95% CI 0.3–2.2). The study could effectively rule out a relative risk greater than 2.5 for all malformations. Rates of preterm delivery or growth retardation did not differ between the groups.

A controlled prospective observational study followed 113 women exposed to omeprazole during pregnancy (89% first trimester exposures). The reported rates of major congenital malformations was 4% for the omeprazole group, 2% for controls exposed to non-teratogens, and 2.8% in disease-paired controls (background incidence of major malformations 1–5%). Rates of spontaneous and elective abortions, preterm deliveries, gestational age at delivery, and mean birth weight did not differ between the groups. The sample size in this study has 80% power to detect a 5-fold increase in the rate of major malformation.

Several studies have reported no apparent adverse short-term effects on the infant when single dose oral or intravenous omeprazole was administered to over 200 pregnant women as premedication for cesarean section under general anesthesia.

Reproductive studies conducted with omeprazole on rats at oral doses up to 56 times the human dose and in rabbits at doses up to 56 times the human dose did not show any evidence of teratogenicity. In pregnant rabbits, omeprazole at doses about 5.5 to 56 times the human dose produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy loss. In rats treated with omeprazole at doses about 5.6 to 56 times the human dose, dose-related embryo/fetal toxicity and postnatal developmental toxicity occurred in offspring. [See *Animal Toxicology and/or Pharmacology* (13.2)].

### **8.3 Nursing Mothers**

Omeprazole concentrations have been measured in breast milk of a woman following oral administration of 20 mg. The peak concentration of omeprazole in breast milk was less than 7% of the peak serum concentration. This concentration would correspond to 0.004 mg of omeprazole in 200 mL of milk. Because omeprazole is excreted in human milk, because of the potential for serious adverse reactions in nursing infants from omeprazole, and because of the potential for tumorigenicity shown for omeprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

## 8.4 Pediatric Use

Use of Omeprazole Delayed-Release Capsules in pediatric and adolescent patients 2 to 16 years of age for the treatment of GERD is supported by a) extrapolation of results, already included in the currently approved labeling, from adequate and well-controlled studies that supported the approval of Omeprazole Delayed-Release Capsules for adults, and b) safety and pharmacokinetic studies performed in pediatric and adolescent patients. [See Clinical Pharmacology, Pharmacokinetics, Pediatric for pharmacokinetic information (12.3) and Dosage and Administration (2). Adverse Reactions (6.1) and Clinical Studies, (14.6)]. The safety and effectiveness of Omeprazole Delayed-Release Capsules for the treatment of GERD in patients < 1 year of age have not been established. The safety and effectiveness of Omeprazole Delayed-Release Capsules for other pediatric uses have not been established.

## 8.5 Geriatric Use

Omeprazole was administered to over 2000 elderly individuals ( $\geq 65$  years of age) in clinical trials in the U.S. and Europe. There were no differences in safety and effectiveness between the elderly and younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

Pharmacokinetic studies have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers. However, no dosage adjustment is necessary in the elderly. [See Clinical Pharmacology (12.3)]

## 8.6 Hepatic Impairment

Consider dose reduction, particularly for maintenance of healing of erosive esophagitis. [See Clinical Pharmacology (12.3)]

## 8.7 Renal Impairment

No dosage reduction is necessary. [See Clinical Pharmacology (12.3) ]

## 8.8 Asian Population

Consider dose reduction, particularly for maintenance of healing of erosive esophagitis. [See Clinical Pharmacology (12.3) ]

## 10 OVERDOSAGE


Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience. [See Adverse Reactions (6)] Symptoms were transient, and no serious clinical outcome has been reported when Omeprazole Delayed-Release Capsules were taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.

As with the management of any overdose, the possibility of multiple drug ingestion should be considered. For current information on treatment of any drug overdose, contact a Poison Control Center at 1-800-222-1222.

Single oral doses of omeprazole at 1350, 1339, and 1200 mg/kg were lethal to mice, rats, and dogs, respectively. Animals given these doses showed sedation, ptosis, tremors, convulsions, and decreased activity, body temperature, and respiratory rate and increased depth of respiration.

## 11 DESCRIPTION

The active ingredient in Omeprazole Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is  $C_{17}H_{19}N_3O_3S$ , with a molecular weight of 345.42. The structural formula is:



Omeprazole is a white to off-white crystalline powder that melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of omeprazole is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.

Omeprazole Delayed-Release Capsules meet USP Dissolution Test 2.

Omeprazole Delayed-Release Capsules are for oral administration. Each delayed-release capsule contains either 10 mg, 20 mg or 40 mg of omeprazole in the form of enteric-coated microtablets with the following inactive ingredients: crospovidone, glyceryl behenate, hypromellose, lactose monohydrate, methacrylic acid copolymer dispersion, silicon dioxide, talc, titanium dioxide and triethyl citrate. The capsule shells have the following inactive ingredients: gelatin, titanium dioxide, sodium lauryl sulfate, synthetic black iron oxide, shellac glaze, and other inactive ingredients. In addition, the 20 mg and 40 mg capsules shells also contain yellow iron oxide.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the  $H^+/K^+$  ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Animal studies indicate that after rapid disappearance from plasma, omeprazole can be found within the gastric mucosa for a day or more.

#### *Antisecretory Activity*

After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal  $H^+/K^+$  ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days.

Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in normal volunteers and patients are shown below. The “max” value represents determinations at a time of maximum effect (2-6 hours after dosing), while “min” values are those 24

hours after the last dose of omeprazole.

**Table 1 Range of Mean Values from Multiple Studies of the Mean Antisecretory Effects of Omeprazole After Multiple Daily Dosing**

Parameter	Omeprazole 20 mg		Omeprazole 40 mg	
	Max	Min	Max	Min
% Decrease in Basal Acid Output	78*	58–80	94*	80–93
% Decrease in Peak Acid Output	79*	50–59	88*	62–68
% Decrease in 24-hr Intra-gastric Acidity		80–97		92–94

\* Single Studies

Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intra-gastric acidity in some patients.

#### *Serum Gastric Effects*

In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H<sub>2</sub>-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.

#### *Enterochromaffin-like (ECL) Cell Effects*

Human gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. [See *Clinical Pharmacology* (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.

#### *Other Effects*

Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.

No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single I.V. dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans.

However, when intra-gastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased.

As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva. All changes resolved within three days of stopping treatment.

The course of Barrett's esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months. No clinically significant impact on Barrett's mucosa by antisecretory therapy was observed. Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett's mucosa was not achieved. No significant difference was observed between treatment groups in development of dysplasia in Barrett's mucosa and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter [See *Clinical Pharmacology* (12)].

## 12.2 Pharmacodynamics

### *Antisecretory Activity*

After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H<sup>+</sup>/K<sup>+</sup> ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days.

Results from numerous studies of the antisecretory effect of multiple doses of 20 mg and 40 mg of omeprazole in normal volunteers and patients are shown below. The "max" value represents determinations at a time of maximum effect (2-6 hours after dosing), while "min" values are those 24 hours after the last dose of omeprazole.

**Table 1 Range of Mean Values from Multiple Studies of the Mean Antisecretory Effects of Omeprazole After Multiple Daily Dosing**

Parameter	Omeprazole 20 mg		Omeprazole 40 mg	
	Max	Min	Max	Min
% Decrease in Basal Acid Output	78*	58-80	94*	80-93
% Decrease in Peak Acid Output	79*	50-59	88*	62-68
% Decrease in 24-hr Intra-gastric Acidity		80-97		92-94

\* Single Studies

Single daily oral doses of omeprazole ranging from a dose of 10 mg to 40 mg have produced 100% inhibition of 24-hour intragastric acidity in some patients.

### *Serum Gastric Effects*

In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H<sub>2</sub>-receptor antagonists, the median increases produced by 20 mg doses of omeprazole were higher (1.3 to 3.6 fold vs. 1.1 to 1.8 fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.

#### *Enterochromaffin-like (ECL) Cell Effects*

Human gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. [See *Clinical Pharmacology* (12)] However, these studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.

#### *Other Effects*

Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.

No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90 mg. In healthy subjects, a single I.V. dose of omeprazole (0.35 mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans.

However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased.

As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva. All changes resolved within three days of stopping treatment.

The course of Barrett's esophagus in 106 patients was evaluated in a U.S. double-blind controlled study of omeprazole 40 mg twice daily for 12 months followed by 20 mg twice daily for 12 months or ranitidine 300 mg twice daily for 24 months. No clinically significant impact on Barrett's mucosa by antisecretory therapy was observed. Although neosquamous epithelium developed during antisecretory therapy, complete elimination of Barrett's mucosa was not achieved. No significant difference was observed between treatment groups in development of dysplasia in Barrett's mucosa and no patient developed esophageal carcinoma during treatment. No significant differences between treatment groups were observed in development of ECL cell hyperplasia, corpus atrophic gastritis, corpus intestinal metaplasia, or colon polyps exceeding 3 mm in diameter [See *Clinical Pharmacology* (12)].

### **12.3 Pharmacokinetics**

#### *Absorption*

Omeprazole Delayed-Release Capsules contain an enteric-coated microtablet formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the microtablets leave the stomach. Absorption is rapid, with peak plasma levels of omeprazole occurring within 0.5 to 3.5 hours. Peak plasma concentrations of omeprazole and AUC are approximately proportional to doses up to 40 mg, but because of a saturable first-pass effect, a greater than linear response in peak plasma concentration and AUC occurs with doses greater than 40 mg. Absolute bioavailability (compared with intravenous administration) is about 30-40% at doses of 20-40 mg, due in large part to presystemic metabolism. In healthy subjects the plasma half-life is 0.5 to 1 hour, and the total body clearance is 500-600 mL/min.

The bioavailability of omeprazole increases slightly upon repeated administration of Omeprazole Delayed-Release Capsules.

Omeprazole Delayed-Release Capsules 40 mg was bioequivalent when administered with and without applesauce. However, Omeprazole Delayed-Release Capsules 20 mg was not bioequivalent when administered with and without applesauce. When administered with applesauce, a mean 25% reduction in  $C_{max}$  was observed without a significant change in AUC for Omeprazole Delayed-Release Capsules 20 mg. The clinical relevance of this finding is unknown.

#### *Distribution*

Protein binding is approximately 95%.

#### *Metabolism*

Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system.

#### *Excretion*

Following single dose oral administration of a buffered solution of omeprazole, little if any unchanged drug was excreted in urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces. This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma — the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole. These metabolites have very little or no antisecretory activity.

### **Combination Therapy with Antimicrobials**

Omeprazole 40 mg daily was given in combination with clarithromycin 500 mg every 8 hours to healthy adult male subjects. The steady state plasma concentrations of omeprazole were increased ( $C_{max}$ ,  $AUC_{0-24}$ , and  $T_{1/2}$  increases of 30%, 89% and 34% respectively) by the concomitant administration of clarithromycin. The observed increases in omeprazole plasma concentration were associated with the following pharmacological effects. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when co-administered with clarithromycin.

The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean  $C_{max}$  was 10% greater, the mean  $C_{min}$  was 27% greater, and the mean  $AUC_{0-8}$  was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean  $C_{max}$  was 45% greater, the mean  $C_{min}$  was 57% greater, and the mean  $AUC_{0-8}$  was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.

**Table 2 Clarithromycin Tissue Concentrations 2 hours after Dose\***

<b>Tissue</b>	<b>Clarithromycin</b>	<b>Clarithromycin + Omeprazole</b>
Antrum	10.48 ± 2.01 (n = 5)	19.96 ± 4.71 (n=5)
Fundus	20.81 ± 7.64 (n = 5)	24.25 ± 6.37 (n= 5)
Mucus	4.15 ± 7.74 (n = 4)	39.29 ± 32.79 (n=4)

\* Mean ± SD (µg/g)

### **Special Populations**

#### **Geriatric Population**

The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was



increased. Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly volunteers, versus 58% in young volunteers given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers.

The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased. Omeprazole was 76% bioavailable when a single 40 mg oral dose of omeprazole (buffered solution) was administered to healthy elderly volunteers, versus 58% in young volunteers given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole and no unchanged drug was detected. The plasma clearance of omeprazole was 250 mL/min (about half that of young volunteers) and its plasma half-life averaged one hour, about twice that of young healthy volunteers.

### Pediatric Use

The pharmacokinetics of omeprazole have been investigated in pediatric patients 2 to 16 years of age:

**Table 3 Pharmacokinetic Parameters of Omeprazole Following Single and Repeated Oral Administration in Pediatric Populations Compared with Adults**

Single or Repeated Oral Dosing /Parameter	Children* ≤ 20 kg 2-5 years	Children* > 20 kg 6-16 years	Adults† (mean 76 kg) 23-29 years (n=12)
	10 mg	20 mg	
Single Dosing			
C <sub>max</sub> ‡(ng/mL)	288 (n=10)	495 (n=49)	668
AUC‡(ng h/mL)	511 (n=7)	1140 (n=32)	1220
Repeated Dosing			
C <sub>max</sub> ‡(ng/mL)	539 (n=4)	851 (n=32)	1458
AUC <sup>c</sup> (ng h/mL)	1179 (n=2)	2276 (n=23)	3352

\* Data from single and repeated dose studies

† Data from a single and repeated dose study Doses of 10, 20 and 40 mg omeprazole as enteric-coated microtablets

‡ Note: ‡ = plasma concentration adjusted to an oral dose of 1 mg/kg.

Following comparable mg/kg doses of omeprazole, younger children (2 to 5 years of age) have lower AUCs than children 6 to 16 years of age or adults; AUCs of the latter two groups did not differ. [See *Dosage and Administration* (2) ]

### Hepatic Impairment

In patients with chronic hepatic disease, the bioavailability increased to approximately 100% compared with an I.V. dose, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared with the half-life in normals of 0.5-1 hour. Plasma clearance averaged 70 mL/min, compared with a value of 500-600 mL/min in normal subjects. Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for the hepatically impaired should be considered.

In patients with chronic hepatic disease, the bioavailability increased to approximately 100% compared

with an I.V. dose, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared with the half-life in normals of 0.5-1 hour. Plasma clearance averaged 70 mL/min, compared with a value of 500-600 mL/min in normal subjects. Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for the hepatically impaired should be considered.

### **Renal Impairment**

In patients with chronic renal impairment, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m<sup>2</sup>, the disposition of omeprazole was very similar to that in healthy volunteers, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. No dose reduction is necessary in patients with renal impairment.

In patients with chronic renal impairment, whose creatinine clearance ranged between 10 and 62 mL/min/1.73 m<sup>2</sup>, the disposition of omeprazole was very similar to that in healthy volunteers, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. No dose reduction is necessary in patients with renal impairment.

### **Asian Population**

In pharmacokinetic studies of single 20 mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared with Caucasians. Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for Asian subjects should be considered.

In pharmacokinetic studies of single 20 mg omeprazole doses, an increase in AUC of approximately four-fold was noted in Asian subjects compared with Caucasians. Dose reduction, particularly where maintenance of healing of erosive esophagitis is indicated, for Asian subjects should be considered.

## **12.4 Microbiology Information in H. pylori**

Omeprazole and clarithromycin dual therapy and omeprazole, clarithromycin and amoxicillin triple therapy have been shown to be active against most strains of *Helicobacter pylori* *in vitro* and in clinical infections as described in the *Indications and Usage* section (1.1).

### *Helicobacter*

#### *Helicobacter pylori*- Pretreatment Resistance

Clarithromycin pretreatment resistance rates were 3.5% (4/113) in the omeprazole/clarithromycin dual therapy studies (4 and 5) and 9.3% (41/439) in omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3).

Amoxicillin pretreatment susceptible isolates ( $\leq 0.25$   $\mu\text{g/mL}$ ) were found in 99.3% (436/439) of the patients in the omeprazole/clarithromycin/amoxicillin triple therapy studies (1, 2, and 3). Amoxicillin pretreatment minimum inhibitory concentrations (MICs)  $> 0.25$   $\mu\text{g/mL}$  occurred in 0.7% (3/439) of the patients, all of whom were in the clarithromycin and amoxicillin study arm. One patient had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of  $> 256$   $\mu\text{g/mL}$  by Etest<sup>®</sup>.

**Table 4 Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes**

---

### **Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes\***

---

<b>Clarithromycin Pretreatment Results</b>	<b>Clarithromycin Post-</b>
--	-----------------------------

<b>treatment Results</b>					
	<i>H. pylori</i> negative – eradicated	<i>H. pylori</i> positive – not eradicated			
		Post-treatment susceptibility results			
		S <sup>†</sup>	I <sup>†</sup>	R <sup>†</sup>	No MIC
Dual Therapy – (omeprazole 40 mg once daily/clarithromycin 500 mg three times daily for 14 days followed by omeprazole 20 mg once daily for another 14 days) (Studies M93-067, M93-100)					
Susceptible †108	72	1		26	9
Intermediate †1				1	
Resistant †4				4	
Triple Therapy – (omeprazole 20 mg twice daily/clarithromycin 500 mg twice daily/amoxicillin 1 g twice daily for 10 days – Studies 126, 127, M96-446; followed by omeprazole 20 mg once daily for another 18 days – Studies 126, 127)					
Susceptible †171	153	7		3	8
Intermediate †					
Resistant †14	4	1		6	3
* Includes only patients with pretreatment clarithromycin susceptibility test results					
† Susceptible (S) MIC ≤ 0.25 µg/mL, Intermediate (I) MIC 0.5 – 1.0 µg/mL, Resistant (R) MIC ≥ 2 µg/mL					

Patients not eradicated of *H. pylori* following omeprazole/clarithromycin/amoxicillin triple therapy or omeprazole/clarithromycin dual therapy will likely have clarithromycin resistant *H. pylori* isolates. Therefore, clarithromycin susceptibility testing should be done, if possible. Patients with clarithromycin resistant *H. pylori* should not be treated with any of the following: omeprazole/clarithromycin dual therapy, omeprazole/clarithromycin/amoxicillin triple therapy, or other regimens which include clarithromycin as the sole antimicrobial agent.

#### *Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes*

In the triple therapy clinical trials, 84.9% (157/185) of the patients in the omeprazole/clarithromycin/amoxicillin treatment group who had pretreatment amoxicillin susceptible MICs (≤ 0.25 µg/mL) were eradicated of *H. pylori* and 15.1% (28/185) failed therapy. Of the 28 patients who failed triple therapy, 11 had no post-treatment susceptibility test results and 17 had post-treatment *H. pylori* isolates with amoxicillin susceptible MICs. Eleven of the patients who failed triple therapy also had post-treatment *H. pylori* isolates with clarithromycin resistant MICs.

#### *Susceptibility Test for Helicobacter pylori*

The reference methodology for susceptibility testing of *H. pylori* is agar dilution MICs<sup>1</sup>. One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 10<sup>7</sup> - 1 x 10<sup>8</sup> CFU/mL for *H. pylori*) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (≥ 2 weeks old). The agar dilution plates are incubated at 35°C in a microaerobic environment produced by a gas generating system suitable for campylobacters. After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria:

**Table 5**

Clarithromycin MIC ( $\mu\text{g/mL}$ ) *	Interpretation
$\leq 0.25$	Susceptible (S)
0.5	Intermediate (I)
$> 1.0$	Resistant (R)
Amoxicillin MIC ( $\mu\text{g/mL}$ ) *,†	Interpretation
$\leq 0.25$	Susceptible (S)

\* These are tentative breakpoints for the agar dilution methodology and they should not be used to interpret results obtained using alternative methods.

† There were not enough organisms with MICs  $> 0.25 \mu\text{g/mL}$  to determine a resistance breakpoint.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard clarithromycin and amoxicillin powders should provide the following MIC values:

Microorganism	Antimicrobial Agent	MIC ( $\mu\text{g/mL}$ ) *
<i>H. pylori</i> ATCC 43504	Clarithromycin	0.016- 0.12 ( $\mu\text{g/mL}$ )
<i>H. pylori</i> ATCC 43504	Amoxicillin	0.016- 0.12 ( $\mu\text{g/mL}$ )

\* These are quality control ranges for the agar dilution methodology and they should not be used to control test results obtained using alternative methods.

### *Effects on Gastrointestinal Microbial Ecology*

Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as *Salmonella* and *Campylobacter*.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

In two 24-month carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44.0 and 140.8 mg/kg/day (about 0.7 to 57 times a human dose of 20 mg/day, as expressed on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (about 6 times a human dose of 20 mg/day, based on body surface area) for one year, and then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell hyperplasia was observed at the end of one year (94% treated vs 10% controls). By the second year the difference between treated and control rats was much smaller (46% vs 26%) but still showed more hyperplasia in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for two years. For this strain of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. In a 52-week toxicity study in Sprague-Dawley rats, brain astrocytomas were found in a small number of males that received omeprazole at dose levels of 0.4, 2,

and 16 mg/kg/day (about 0.2 to 6.5 times the human dose on a body surface area basis). No astrocytomas were observed in female rats in this study. In a 2-year carcinogenicity study in Sprague-Dawley rats, no astrocytomas were found in males or females at the high dose of 140.8 mg/kg/day (about 57 times the human dose on a body surface area basis). A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive. A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.

Omeprazole was positive for clastogenic effects in an *in vitro* human lymphocyte chromosomal aberration assay, in one of two *in vivo* mouse micronucleus tests, and in an *in vivo* bone marrow cell chromosomal aberration assay. Omeprazole was negative in the *in vitro* Ames test, an *in vitro* mouse lymphoma cell forward mutation assay, and an *in vivo* rat liver DNA damage assay.

Omeprazole at oral doses up to 138 mg/kg/day in rats (about 56 times the human dose on a body surface area basis) was found to have no effect on fertility and reproductive performance.

In 24-month carcinogenicity studies in rats, a dose-related significant increase in gastric carcinoid tumors and ECL cell hyperplasia was observed in both male and female animals [See [Warnings and Precautions\(5\)](#) ] Carcinoid tumors have also been observed in rats subjected to fundectomy or long-term treatment with other proton pump inhibitors or high doses of H<sub>2</sub>-receptor antagonists.

## 13.2 Animal Toxicology and/or Pharmacology

### *Reproductive Toxicology Studies*

Reproductive studies conducted with omeprazole in rats at oral doses up to 138 mg/kg/day (about 56 times the human dose on a body surface area basis) and in rabbits at doses up to 69 mg/kg/day (about 56 times the human dose on a body surface area basis) did not disclose any evidence for a teratogenic potential of omeprazole. In rabbits, omeprazole in a dose range of 6.9 to 69.1 mg/kg/day (about 5.5 to 56 times the human dose on a body surface area basis) produced dose-related increases in embryo-lethality, fetal resorptions, and pregnancy disruptions. In rats, dose-related embryo/fetal toxicity and postnatal developmental toxicity were observed in offspring resulting from parents treated with omeprazole at 13.8 to 138.0 mg/kg/day (about 5.6 to 56 times the human doses on a body surface area basis).

## 14 CLINICAL STUDIES

### 14.1 Duodenal Ulcer Disease

*Active Duodenal Ulcer*—In a multicenter, double-blind, placebo-controlled study of 147 patients with endoscopically documented duodenal ulcer, the percentage of patients healed (per protocol) at 2 and 4 weeks was significantly higher with omeprazole 20 mg once daily than with placebo ( $p \leq 0.01$ ).

#### **Treatment of Active Duodenal Ulcer % of Patients Healed**

	Omeprazole 20 mg a.m. (n=99)	Placebo a.m. (n=48)
Week 2	*41	13
Week 4	*75	27

\*( $p \leq 0.01$ )

Complete daytime and nighttime pain relief occurred significantly faster ( $p \leq 0.01$ ) in patients treated with omeprazole 20 mg than in patients treated with placebo. At the end of the study, significantly more patients who had received omeprazole had complete relief of daytime pain ( $p \leq 0.05$ ) and nighttime pain

( $p \leq 0.01$ ).

In a multicenter, double-blind study of 293 patients with endoscopically documented duodenal ulcer, the percentage of patients healed (per protocol) at 4 weeks was significantly higher with omeprazole 20 mg once daily than with ranitidine 150 mg b.i.d. ( $p < 0.01$ ).

#### **Treatment of Active Duodenal Ulcer % of Patients Healed**

	<b>Omeprazole</b>	<b>Ranitidine</b>
	20 mg a.m.	150 mg twice daily
	(n = 145)	(n = 148)
Week 2	42	34
Week 4	*82	63

\*( $p < 0.01$ )

Healing occurred significantly faster in patients treated with omeprazole than in those treated with ranitidine 150 mg b.i.d. ( $p < 0.01$ ).

In a foreign multinational randomized, double-blind study of 105 patients with endoscopically documented duodenal ulcer, 20 mg and 40 mg of omeprazole were compared with 150 mg b.i.d. of ranitidine at 2, 4 and 8 weeks. At 2 and 4 weeks both doses of omeprazole were statistically superior (per protocol) to ranitidine, but 40 mg was not superior to 20 mg of omeprazole, and at 8 weeks there was no significant difference between any of the active drugs.

#### **Treatment of Active Duodenal Ulcer % of Patients Healed**

	<b>Omeprazole</b>		<b>Ranitidine</b>
	20 mg (n=34)	40 mg (n=36)	150 mg twice daily (n=35)
Week 2	*83	*83	53
Week 4	*97	*100	82
Week 8	100	100	94

\*( $p \leq 0.01$ )

#### *H. pylori Eradication in Patients with Duodenal Ulcer Disease*

*Triple Therapy (omeprazole/clarithromycin/amoxicillin)*— Three U.S., randomized, double-blind clinical studies in patients with *H. pylori* infection and duodenal ulcer disease (n=558) compared omeprazole plus clarithromycin plus amoxicillin with clarithromycin plus amoxicillin. Two studies (1 and 2) were conducted in patients with an active duodenal ulcer, and the other study (3) was conducted in patients with a history of a duodenal ulcer in the past 5 years but without an ulcer present at the time of enrollment. The dose regimen in the studies was omeprazole 20 mg twice daily plus clarithromycin 500 mg twice daily plus amoxicillin 1 g twice daily for 10 days; or clarithromycin 500 mg twice daily, plus amoxicillin 1 g twice daily for 10 days. In studies 1 and 2, patients who took the omeprazole regimen

also received an additional 18 days of omeprazole 20 mg once daily. Endpoints studied were eradication of *H. pylori* and duodenal ulcer healing (studies 1 and 2 only). *H. pylori* status was determined by CLOtest<sup>®</sup>, histology and culture in all three studies. For a given patient, *H. pylori* was considered eradicated if at least two of these tests were negative, and none was positive.

The combination of omeprazole plus clarithromycin plus amoxicillin was effective in eradicating *H. pylori*.

**Table 6**

Per-Protocol and Intent-to-Treat <i>H. pylori</i> Eradication Rates % of Patients Cured [95% Confidence Interval]				
	omeprazole +clarithromycin +amoxicillin		clarithromycin +amoxicillin	
	Per-Protocol *	Intent-to-Treat †	Per-Protocol *	Intent-to-Treat †
Study 1	‡77 [64, 86] (n = 64)	‡69 [57, 79] (n = 80)	43 [31, 56] (n = 67)	37 [27, 48] (n = 84)
Study 2	‡78 [67, 88] (n = 65)	‡73 [61, 82] (n = 77)	41 [29, 54] (n = 68)	36 [26, 47] (n = 83)
Study 3	‡90 [80, 96] (n = 69)	‡83 [74, 91] (n = 84)	33 [24, 44] (n = 93)	32 [23, 42] (n = 99)

\* Patients were included in the analysis if they had confirmed duodenal ulcer disease (active ulcer, studies 1 and 2; history of ulcer within 5 years, study 3) and *H. Pylori* infection at baseline defined as at least two of three positive endoscopic tests from CLOtest<sup>®</sup>, histology, and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the analysis as failures of therapy. The impact of eradication on ulcer recurrence has not been assessed in patients with a past history of ulcer.

† Patients were included in the analysis if they had documented *H. Pylori* infection at baseline and had confirmed duodenal ulcer disease. All dropouts were included as failures of therapy.

‡ (p < 0.05) versus clarithromycin plus amoxicillin.

#### Dual Therapy (omeprazole/clarithromycin)

Four randomized, double-blind, multi-center studies (4, 5, 6, and 7) evaluated omeprazole 40 mg once daily plus clarithromycin 500 mg three times daily for 14 days, followed by omeprazole 20 mg once daily, (studies 4, 5, and 7) or by omeprazole 40 mg once daily (Study 6) for an additional 14 days in patients with active duodenal ulcer associated with *H. pylori*. Studies 4 and 5 were conducted in the U.S. and Canada and enrolled 242 and 256 patients, respectively. *H. pylori* infection and duodenal ulcer were confirmed in 219 patients in Study 4 and 228 patients in Study 5. These studies compared the combination regimen to omeprazole and clarithromycin monotherapies. Studies 6 and 7 were conducted in Europe and enrolled 154 and 215 patients, respectively. *H. pylori* infection and duodenal ulcer were confirmed in 148 patients in study 6 and 208 patients in Study 7. These studies compared the combination regimen with omeprazole monotherapy. The results for the efficacy analyses for these studies are described below. *H. pylori* eradication was defined as no positive test (culture or histology) at 4 weeks following the end of treatment, and two negative tests were required to be considered eradicated of *H. pylori*. In the per-protocol analysis, the following patients were excluded: dropouts,

patients with missing *H. pylori* tests post-treatment, and patients that were not assessed for *H. pylori* eradication because they were found to have an ulcer at the end of treatment.

The combination of omeprazole and clarithromycin was effective in eradicating *H. pylori*.

**Table 7**

***H. pylori* Eradication Rates (Per-Protocol Analysis at 4 to 6 Weeks) % of Patients Cured [95% Confidence Interval]**

	omeprazole +clarithromycin	omeprazole	clarithromycin
<b>U.S. Studies</b>			
Study 4	74 [60, 85] <sup>*†</sup> (n=53)	0 [0, 7] (n=54)	31 [18, 47] (n=42)
Study 5	64 [51, 76] <sup>*†</sup> (n=61)	0 [0, 6] (n=59)	39 [24, 55] (n=44)
<b>Non U.S. Studies</b>			
Study 6	83 [71, 92] <sup>†</sup> (n=60)	1[0, 7] (n=74)	N/A
Study 7	74 [64, 83] <sup>†</sup> (n=86)	1[0, 6] (n=90)	N/A

\* Statistically significantly higher than clarithromycin monotherapy (p < 0.05)

† Statistically significantly higher than omeprazole monotherapy (p < 0.05)

Ulcer healing was not significantly different when clarithromycin was added to omeprazole therapy compared with omeprazole therapy alone.

The combination of omeprazole and clarithromycin was effective in eradicating *H. pylori* and reduced duodenal ulcer recurrence.

**Table 8**

**Duodenal Ulcer Recurrence Rates by *H. pylori* Eradication Status**

**% of Patients with Ulcer Recurrence**

	<i>H. pylori</i> eradicated *	<i>H. pylori</i> not eradicated *
<b>U.S. Studies<sup>†</sup> 6 months post-treatment</b>		
Study 4	‡35 (n=49)	60 (n=88)
Study 5	‡8 (n=53)	60 (n=106)
<b>Non U.S. Studies<sup>§</sup> 6 months post-treatment</b>		
Study 6	‡5 (n=43)	46 (n=78)



Study 7	‡6 (n=53)	43 (n=107)
12 months post-treatment		
Study 6	‡5 (n=39)	68 (n=71)

\* *H. pylori* eradication status assessed at same time point as ulcer recurrence

† Combined results for omeprazole + clarithromycin, omeprazole, and clarithromycin treatment arms

‡ ( $p \leq 0.01$ ) versus proportion with duodenal ulcer recurrence who were not *H. pylori* eradicated

§ Combined results for omeprazole + clarithromycin and omeprazole treatment arms

## 14.2 Gastric Ulcer

In a U.S. multicenter, double-blind, study of omeprazole 40 mg once daily, 20 mg once daily, and placebo in 520 patients with endoscopically diagnosed gastric ulcer, the following results were obtained.

<b>Treatment of Gastric Ulcer</b>			
<b>% of Patients Healed (All Patients Treated)</b>			
	Omeprazole 20 mg once daily (n=202)	Omeprazole 40 mg once daily (n=214)	Placebo (n=104)
Week 4	47.5 *	55.6 *	30.8
Week 8	74.8 *	82.7 *†	48.1

\* ( $p < 0.01$ ) Omeprazole 40 mg or 20 mg versus placebo

† ( $p < 0.05$ ) Omeprazole 40 mg versus 20 mg

For the stratified groups of patients with ulcer size less than or equal to 1 cm, no difference in healing rates between 40 mg and 20 mg was detected at either 4 or 8 weeks. For patients with ulcer size greater than 1 cm, 40 mg was significantly more effective than 20 mg at 8 weeks.

In a foreign, multinational, double-blind study of 602 patients with endoscopically diagnosed gastric ulcer, omeprazole 40 mg once daily, 20 mg once daily, and ranitidine 150 mg twice a day were evaluated.

<b>Treatment of Gastric Ulcer</b>			
<b>% of Patients Healed (All Patients Treated)</b>			
	Omeprazole 20 mg once daily (n=200)	Omeprazole 40 mg once daily (n=187)	Ranitidine 150 mg twice daily. (n=199)
Week 4	63.5	78.1 *†	56.3
Week 8	81.5	91.4 *†	78.4

\* ( $p < 0.01$ ) Omeprazole 40 mg versus ranitidine

† ( $p < 0.01$ ) Omeprazole 40 mg versus 20 mg

## 14.3 Gastroesophageal Reflux Disease (GERD)

### Symptomatic GERD

A placebo-controlled study was conducted in Scandinavia to compare the efficacy of omeprazole 20 mg or 10 mg once daily for up to 4 weeks in the treatment of heartburn and other symptoms in GERD patients without erosive esophagitis. Results are shown below.

#### % Successful Symptomatic Outcome \*

	<b>Omeprazole 20 mg a.m.</b>	<b>Omeprazole 10 mg a.m.</b>	<b>Placebo a.m.</b>
All patients	46 †‡ (n=205)	31‡ (n=199)	13 (n=105)
Patients with confirmed GERD	56 †‡ (n=115)	36 ‡ (n=109)	14 (n=59)

\* Defined as complete resolution of heartburn

† (p < 0.005) versus 10 mg

‡ (p < 0.005) versus placebo

### 14.4 Erosive Esophagitis

In a U.S. multicenter double-blind placebo controlled study of 20 mg or 40 mg of omeprazole in patients with symptoms of GERD and endoscopically diagnosed erosive esophagitis of grade 2 or above, the percentage healing rates (per protocol) were as follows:

Week	20 mg Omeprazole (n=83)	40 mg Omeprazole (n=87)	Placebo (n=43)
4	39 *	45 *	7
8	74 *	75 *	14

\* (p < 0.01) Omeprazole versus placebo.

In this study, the 40 mg dose was not superior to the 20 mg dose of omeprazole in the percentage healing rate. Other controlled clinical trials have also shown that omeprazole is ineffective in severe GERD. In comparisons with histamine H<sub>2</sub>-receptor antagonists in patients with erosive esophagitis, grade 2 or above, omeprazole in a dose of 20 mg was significantly more effective than the active controls. Complete daytime and nighttime heartburn relief occurred significantly faster (p < 0.01) in patients treated with omeprazole than in those taking placebo or histamine H<sub>2</sub>-receptor antagonists.

In this and five other controlled GERD studies, significantly more patients taking 20 mg omeprazole (84%) reported complete relief of GERD symptoms than patients receiving placebo (12%).

#### Long Term Maintenance Of Healing of Erosive Esophagitis

In a U.S. double-blind, randomized, multicenter, placebo controlled study, two dose regimens of omeprazole were studied in patients with endoscopically confirmed healed esophagitis. Results to determine maintenance of healing of erosive esophagitis are shown below.

#### Life Table Analysis

	<b>Omeprazole 20 mg once daily (n=138)</b>	<b>Omeprazole 20 mg 3 days per week (n=137)</b>	<b>Placebo (n=131)</b>
Percent in endoscopic remission at 6 months	*70	34	11

\* ( $p < 0.01$ ) Omeprazole 20 mg once daily versus Omeprazole 20 mg 3 consecutive days per week or placebo.

In an international multicenter double-blind study, omeprazole 20 mg daily and 10 mg daily were compared with ranitidine 150 mg twice daily in patients with endoscopically confirmed healed esophagitis. The table below provides the results of this study for maintenance of healing of erosive esophagitis.

#### Life Table Analysis

	<b>Omeprazole 20 mg once daily (n=131)</b>	<b>Omeprazole 10 mg once daily (n=133)</b>	<b>Ranitidine 150 mg twice daily (n=128)</b>
Percent in endoscopic remission at 12 months	*77	†58	46

\* ( $p = 0.01$ ) Omeprazole 20 mg once daily, versus Omeprazole 10 mg-once daily or Ranitidine

† ( $p = 0.03$ ) Omeprazole 10 mg once daily, versus Ranitidine

In patients who initially had grades 3 or 4 erosive esophagitis, for maintenance after healing, 20 mg daily of Omeprazole was effective, while 10 mg did not demonstrate effectiveness.

#### 14.5 Pathological Hypersecretory Conditions

In open studies of 136 patients with pathological hypersecretory conditions, such as Zollinger-Ellison (ZE) syndrome with or without multiple endocrine adenomas, omeprazole significantly inhibited gastric acid secretion and controlled associated symptoms of diarrhea, anorexia, and pain. Doses ranging from 20 mg every other day to 360 mg per day maintained basal acid secretion below 10 mEq/hr in patients without prior gastric surgery, and below 5 mEq/hr in patients with prior gastric surgery.

Initial doses were titrated to the individual patient need, and adjustments were necessary with time in some patients [see *Dosage and Administration* (2)]. Omeprazole was well tolerated at these high dose levels for prolonged periods (> 5 years in some patients). In most ZE patients, serum gastrin levels were not modified by omeprazole. However, in some patients serum gastrin increased to levels greater than those present prior to initiation of omeprazole therapy. At least 11 patients with ZE syndrome on long-term treatment with omeprazole developed gastric carcinoids. These findings are believed to be a manifestation of the underlying condition, which is known to be associated with such tumors, rather than the result of the administration of omeprazole. [See *6 Adverse Reactions* (6)]

#### 14.6 Pediatric GERD

##### *Symptomatic GERD*

The effectiveness of Omeprazole Delayed-Release Capsules for the treatment of nonerosive GERD in pediatric patients 2 to 16 years of age is based in part on data obtained from pediatric patients in an uncontrolled Phase III studies. [See *Use in Specific Populations* (8.4)]

The study enrolled 113 pediatric patients 2 to 16 years of age with a history of symptoms suggestive of nonerosive GERD. Patients were administered a single dose of omeprazole (10 mg or 20 mg, based on body weight) for 4 weeks either as an intact capsule or as an open capsule in applesauce. Successful response was defined as no moderate or severe episodes of either pain-related symptoms or vomiting/regurgitation during the last 4 days of treatment. Results showed success rates of 60% (9/15; 10 mg omeprazole) and 59% (58/98; 20 mg omeprazole), respectively.

### *Healing of Erosive Esophagitis*

In an uncontrolled, open-label dose-titration study, healing of erosive esophagitis in pediatric patients 1 to 16 years of age required doses that ranged from 0.7 to 3.5 mg/kg/day (80 mg/day). Doses were initiated at 0.7 mg/kg/day. Doses were increased in increments of 0.7 mg/kg/day (if intraesophageal pH showed a pH of < 4 for less than 6% of a 24-hour study). After titration, patients remained on treatment for 3 months. Forty-four percent of the patients were healed on a dose of 0.7 mg/kg body weight; most of the remaining patients were healed with 1.4 mg/kg after an additional 3 months' treatment. Erosive esophagitis was healed in 51 of 57 (90%) children who completed the first course of treatment in the healing phase of the study. In addition, after 3 months of treatment, 33% of the children had no overall symptoms, 57% had mild reflux symptoms, and 40% had less frequent regurgitation/vomiting.

### *Maintenance of Healing of Erosive Esophagitis*

In an uncontrolled, open-label study of maintenance of healing of erosive esophagitis in 46 pediatric patients, 54% of patients required half the healing dose. The remaining patients increased the healing dose (0.7 to a maximum of 2.8 mg/kg/day) either for the entire maintenance period, or returned to half the dose before completion. Of the 46 patients who entered the maintenance phase, 19 (41%) had no relapse. In addition, maintenance therapy in erosive esophagitis patients resulted in 63% of patients having no overall symptoms.

## 15 REFERENCES

1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically—Fifth Edition. Approved Standard NCCLS Document M7-A5, Vol, 20, No. 2, NCCLS, Wayne, PA, January 2000.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

Omeprazole Delayed-Release Capsules, 10 mg, are opaque white cap and opaque white body capsules imprinted with “KU” and “114” in black ink. They are supplied as follows:

Omeprazole Delayed-Release Capsules, 20 mg, are opaque white cap and opaque gold body capsules imprinted with “KU” and “118” in black ink. They are supplied as follows:

Omeprazole Delayed-Release Capsules, 40 mg, are opaque gold cap and opaque gold body capsules imprinted with “KU” and “136” in black ink. They are supplied as follows:

They are supplied by **Altura Pharmaceuticals, Inc.** as follows:

NDC	Strength	Quantity/Form	Color	Source Prod. Code
63874-553-30	20 mg	30 Capsules in a Plastic Bottle	opaque gold body	62175-118
63874-553-45	20 mg	45 Capsules in a Plastic Bottle	opaque gold body	62175-118
63874-553-60	20 mg	60 Capsules in a Plastic Bottle	opaque gold body	62175-118
63874-553-90	20 mg	90 Capsules in a Plastic Bottle	opaque gold body	62175-118
63874-553-01	20 mg	100 Capsules in a Plastic Bottle	opaque gold body	62175-118

### **Storage**

Store Omeprazole Delayed-Release Capsules in a tight container protected from light and moisture. Store between 15°C and 30°C (59°F and 86°F).

## 17 PATIENT COUNSELING INFORMATION

Omeprazole Delayed-Release Capsule should be taken before eating. Patients should be informed that the Omeprazole Delayed-Release Capsule should be swallowed whole.

For patients who have difficulty swallowing capsules, the contents of a Omeprazole Delayed-Release Capsules can be added to applesauce. One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the microtablets inside the capsule should be carefully emptied on the applesauce. The microtablets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the microtablets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The microtablets should not be chewed or crushed. The microtablets/applesauce mixture should not be stored for future use.

Distributed by:

Kremers Urban, LLC

Princeton, NJ 08540, USA

This Product was Repackaged By:

**Altura Pharmaceuticals, Inc.**

12540 McCann Drive

Santa Fe Springs, CA 90670

United States

## Principal Display Panel - 20 mg Label

**LOT XXXXXXXX EXP XX/XX**

**PHYSICAL DESCRIPTION:**  
Product Description: Color, Shape  
and Imprint Code

**Store at Controlled Room Temp.  
15-30°C (59-86°F)**

**MFG Info:**  
Manufacture NDC  
Mfg Lot: XXXXXXXX  
Manufacture Name

# OMEPRAZOLE DELAYED-RELEASE 20MG CAPSULES


**#30**  
Rx Only **\*\*SAMPLE\*\***  
GENERIC FOR PRILOSEC


ACTIVE INGREDIENTS:  
OMEPRAZOLE 20MG

WARNING: KEEP OUT OF CHILDREN'S REACH.

FOR INDICATIONS, DOSAGE, PRECAUTIONS, ECT., SEE FULL DISCLOSURE BOOK.  
Packaged by Altura Pharmaceuticals, Inc. Santa Fe Springs, CA 90670

NDC 63874-0553-30  
PR# 55330  
Pedigree# 9999999 Rx# XXXXXXXXX  
OMEPRAZOLE DELAYED-RELEASE  
20MG CAPSULES





Altura Pharmaceuticals, Inc.

## OMEPRAZOLE

omeprazole capsule, delayed release

## Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:63874-553(NDC:62175-118)
Route of Administration	ORAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
OMEPRazole (UNII: KG60484QX9) (OMEPRazole - UNII:KG60484QX9)	OMEPRazole	20 mg

## Inactive Ingredients

Ingredient Name	Strength
CROSPVIDONE (UNII: 68401960MK)	
GLYCERYL BEHENATE (UNII: R8WTH25YS2)	
HYPROMELLOSE (UNII: 3NXW29V3WO)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
TALC (UNII: 7SEV7J4RIU)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
TRIETHYL CITRATE (UNII: 8Z96QXD6UM)	
GELATIN (UNII: 2G86QN327L)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
FERROSFERRIC OXIDE (UNII: XM0M87F357)	
SHELLAC (UNII: 46N107B71O)	
FERRIC OXIDE YELLOW (UNII: EX438O2MRT)	

## Product Characteristics

Color	YELLOW (opaque gold body)	Score	no score
Shape	CAPSULE (CAPSULE)	Size	19mm
Flavor		Imprint Code	KU;118
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:63874-553-30	30 in 1 BOTTLE, PLASTIC		
2	NDC:63874-553-45	45 in 1 BOTTLE, PLASTIC		
3	NDC:63874-553-60	60 in 1 BOTTLE, PLASTIC		
4	NDC:63874-553-90	90 in 1 BOTTLE, PLASTIC		
5	NDC:63874-553-01	100 in 1 BOTTLE, PLASTIC		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
--------------------	--	----------------------	--------------------

ANDA	ANDA075410	01/01/2010	
------	------------	------------	--

**Labeler** - Altura Pharmaceuticals, Inc. (006890545)

**Establishment**

Name	Address	ID/FEI	Business Operations
Altura Pharmaceuticals, Inc.		006890545	repack, relabel

Revised: 4/2010

Altura Pharmaceuticals, Inc.